Palemo控股
2778
Spancrete
5277
Renascience
4889
Oncolys BioPharma
4588
北川精機
6327
(FY)2024/03/31 | (Q4)2024/03/31 | (Q3)2023/12/31 | (Q2)2023/09/30 | (Q1)2023/06/30 | (FY)2023/03/31 | (Q4)2023/03/31 | (Q3)2022/12/31 | (Q2)2022/09/30 | (Q1)2022/06/30 | |
---|---|---|---|---|---|---|---|---|---|---|
營業總收入 | 15.72%9.3億 | 16.22%2.52億 | 14.32%2.42億 | 14.67%2.25億 | 17.93%2.12億 | -44.70%8.04億 | -17.88%2.16億 | -34.05%2.12億 | -52.75%1.96億 | -60.43%1.8億 |
主營業務成本 | -14.71%2.64億 | -12.08%5,864.5萬 | -20.49%6,364萬 | -13.82%6,947.9萬 | -12.10%7,238.1萬 | -40.82%3.1億 | -39.91%6,670萬 | -20.13%8,003.6萬 | -44.38%8,061.8萬 | -50.75%8,234.9萬 |
毛利 | 34.80%6.66億 | 28.83%1.93億 | 35.48%1.78億 | 34.58%1.55億 | 43.31%1.4億 | -46.88%4.94億 | -1.84%1.5億 | -40.36%1.32億 | -57.25%1.15億 | -66.07%9,745.9萬 |
營業費用 | -20.34%11.77億 | -29.02%2.52億 | -11.97%3億 | -25.61%2.88億 | -14.61%3.38億 | -30.85%14.77億 | -42.44%3.54億 | -39.92%3.4億 | -19.52%3.87億 | -16.42%3.96億 |
營業利潤 | 48.05%-5.11億 | 71.34%-5,865.6萬 | 41.93%-1.21億 | 51.15%-1.33億 | 33.54%-1.98億 | 18.47%-9.83億 | 55.81%-2.05億 | 39.64%-2.09億 | -28.69%-2.72億 | -60.24%-2.98億 |
營業外利息收入與支出淨額 | 24.73%-374.9萬 | 9.87%-89.5萬 | 23.47%-93.6萬 | 26.74%-90.4萬 | 33.77%-101.4萬 | -23.08%-498.1萬 | -113.61%-99.3萬 | 69.68%-122.3萬 | 70.03%-123.4萬 | 52.01%-153.1萬 |
營業外利息收入 | -13.48%7.7萬 | -33.33%6,000 | --0 | ---- | ---- | -98.43%8.9萬 | -99.84%9,000 | --0 | ---- | ---- |
營業外利息支出 | -24.54%382.6萬 | -10.08%90.1萬 | -23.47%93.6萬 | -25.80%97.5萬 | -33.77%101.4萬 | -47.76%507萬 | 158.43%100.2萬 | -69.68%122.3萬 | -68.70%131.4萬 | -52.01%153.1萬 |
投資淨收益 | ||||||||||
被指定為現金流套期的金融工具損益 | ||||||||||
終止確認可供出售金融資產損益 | ||||||||||
聯營企業及其他參股權益產生的收益 | ||||||||||
特殊收入(費用) | -100.26%-16.8萬 | 0 | 0 | 0 | -100.25%-16.8萬 | 104.79%6,399.1萬 | 96.61%-395.6萬 | 0 | 0 | 6,794.7萬 |
減:其他特殊費用 | ---- | ---- | ---- | ---- | ---- | -114.38%-6,794.7萬 | --0 | --0 | --0 | ---6,794.7萬 |
減:勾銷 | -95.75%16.8萬 | --0 | --0 | --0 | --16.8萬 | -99.54%395.6萬 | -96.94%395.6萬 | --0 | --0 | --0 |
其他營業外收入(費用) | 7.90%1,222萬 | -72.04%168.6萬 | 6,942.21%1,084.5萬 | -85.48%54.7萬 | -162.35%-85.8萬 | 70.69%1,132.5萬 | 127.00%602.9萬 | -98.44%15.4萬 | -80.33%376.6萬 | 2,696.23%137.6萬 |
稅前利潤 | 44.96%-5.02億 | 71.57%-5,786.4萬 | 46.95%-1.11億 | 50.56%-1.33億 | 13.09%-2億 | 64.05%-9.13億 | 65.79%-2.04億 | 41.13%-2.1億 | 80.75%-2.69億 | -21.69%-2.3億 |
所得稅 | -0.38%53.1萬 | 111.21%13.3萬 | -76.96%13.2萬 | -76.66%13.4萬 | -76.92%13.2萬 | 102.34%53.3萬 | -167.04%-118.6萬 | 102.23%57.3萬 | 0.00%57.4萬 | -0.52%57.2萬 |
除稅後利潤 | 44.93%-5.03億 | 71.34%-5,799.7萬 | 47.03%-1.11億 | 50.61%-1.33億 | 13.25%-2億 | 63.70%-9.13億 | 66.09%-2.02億 | 36.37%-2.1億 | 80.71%-2.7億 | -21.62%-2.31億 |
持續經營利潤 | 44.93%-5.03億 | 71.34%-5,799.7萬 | 47.03%-1.11億 | 50.61%-1.33億 | 13.25%-2億 | 63.70%-9.13億 | 66.09%-2.02億 | 36.37%-2.1億 | 80.71%-2.7億 | -21.62%-2.31億 |
歸屬于少數股東的淨利潤 | ||||||||||
歸屬於母公司的淨利潤 | 44.93%-5.03億 | 71.34%-5,799.7萬 | 47.03%-1.11億 | 50.61%-1.33億 | 13.25%-2億 | 63.70%-9.13億 | 66.09%-2.02億 | 36.37%-2.1億 | 80.71%-2.7億 | -21.62%-2.31億 |
優先股派息 | ||||||||||
其他優先股派息 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
歸屬于普通股股東的淨利潤 | 44.93%-5.03億 | 71.34%-5,799.7萬 | 47.03%-1.11億 | 50.61%-1.33億 | 13.25%-2億 | 63.70%-9.13億 | 66.09%-2.02億 | 36.37%-2.1億 | 80.71%-2.7億 | -21.62%-2.31億 |
總派息金額 | ||||||||||
基本每股收益 | 45.12%-38.68 | 71.43%-4.46 | 47.23%-8.56 | 50.77%-10.25 | 13.57%-15.41 | 64.08%-70.48 | 66.09%-15.61 | 35.02%-16.22 | 81.06%-20.82 | -16.54%-17.83 |
稀釋每股收益 | 45.12%-38.68 | 71.43%-4.4605 | 47.22%-8.5613 | 50.78%-10.25 | 13.57%-15.41 | 64.08%-70.48 | 66.11%-15.61 | 36.34%-16.22 | 81.06%-20.8232 | -16.54%-17.83 |
每股派息 | ||||||||||
貨幣單位 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 |
會計準則 | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |